SCHEMBL2760211

SCHEMBL2760211

CC(C)(C)Oc1ccccc1I

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.37
CA1 P00915 3/20 0.36
CA2 P00918 3/20 0.36
CA7 P43166 2/20 0.36
CA9 Q16790 2/20 0.36
CA12 O43570 1/20 0.36
CA4 P22748 1/20 0.36
CA14 Q9ULX7 1/20 0.36
BCHE P06276 1/20 0.33
ACHE P22303 1/20 0.33
FABP7 O15540 1/20 0.32
FABP3 P05413 1/20 0.32
FABP5 Q01469 1/20 0.32
SIGMAR1 Q99720 2/20 0.32
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.32
HSD17B10 Q99714 1/20 0.32
KIF11 P52732 1/20 0.32
IDO1 P14902 2/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29428931 0.82 CA1 (0.45) KCNH2CA1CA2CA7CA9
SCHEMBL3820431 0.82 CA1 (0.45) KCNH2CA1CA2CA7CA9
SCHEMBL26586427 0.79 KCNH2 (0.37) KCNH2
SCHEMBL29344700 0.78 FABP7 (0.33) CA1CA2CA7CA9CA12
SCHEMBL28097271 0.77 FABP7 (0.30) FABP7FABP3FABP5
SCHEMBL14046829 0.77 FABP7 (0.31) CA1CA2CA7CA9CA12
SCHEMBL934639 0.76 SCN9A (0.38) KCNH2ALDH1A1KDM4E
SCHEMBL30740989 0.76 SCN9A (0.38) KCNH2ALDH1A1KDM4E
Methylamine SCHEMBL27640156 0.76 ALDH1A1 (0.37) KCNH2ALDH1A1
SCHEMBL5215818 0.76 KCNH2 (0.35) KCNH2ALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088797-B2 Substituted N-(4-cyano-1H-pyrazol-3-yl)methylamine derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-01-03 US disclosed
US-20100041709-A1 SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-02-18 US disclosed
US-7521581-B2 Catalyst composition and process for producing cross-coupled compound using same TOSOH CORPORATION (JP) 2009-04-21 US disclosed
EP-1707263-B1 Catalyst composition comprising an alkylene diamine-nickel complex and process for producing a cross-coupled compound using the same TOSOH CORP (JP) 2009-02-25 EP disclosed
US-20060224011-A1 Catalyst composition and process for producing cross-coupled compound using same TOSOH CORPORATION 2006-10-05 US disclosed
EP-1707263-A1 Catalyst composition comprising an alkylene diamine-nickel complex and process for producing a cross-coupled compound using the same Tosoh Corporation (JP) 2006-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060224011-A1 Catalyst composition and process for producing cross-coupled compound using same C5, TST, PYM1 KCNH2 234/4885CA1 1677/4885CA2 602/4885
US-20100041709-A1 SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF PRMT3, PRMT5, PRMT1 KCNH2 929/4885CA1 2676/4885CA2 1724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.